Background. Ovarian cancer presents later in the UK compared to economically similar countries. National guidance suggests measuring CA125 in primary care as a means of bringing patients to specialist attention. Aim. To investigate the outcome of CA125 values measured in accordance with this policy. Setting and design. Examination of the laboratory records of female patients from the usual catchment population of one general hospital in whom CA125 was measured from primary care in a calendar year. Methods. Those with values >35 u/ml were identified. Electronic records within the hospital were interrogated to identify what further evaluation had been undertaken whether ovarian or primary peritoneal cancer had been diagnosed or what other pathology was identified. We also reviewed the CA125 measurement history of patients diagnosed over 3 years by any route. Results. One hundred and sixty-four new cases of CA125 ≥35 u/ml were found. Further information was available for 152 of them. Sixteen had ovarian or primary peritoneal cancer and 16 had other cancers. In 50 no cause for the abnormality was found. The remainder had various non-malignant conditions. The specificity for carcinoma of ovary/primary peritoneal carcinoma was 95.4% [95% confidence interval: 94.8-96.0). In a 3-year period, 65 patients were diagnosed with ovarian or primary peritoneal cancer, 5 had values of CA125 between 20 and 35 u/ml shortly before diagnosis. Conclusions. The CA125 level is a useful diagnostic test for ovarian cancer which has been embraced by primary care but higher sensitivity for earlier disease will require strategies to improve the specificity.
Patients with cancer in the UK tend to have poorer survival compared with that seen in economically similar European countries (1) . Evidence points to issues around the diagnosis and initial treatment being the most important factors leading to the shortfall in survival (2) . For ovarian cancer, National Institute of Health and Clinical Excellence (NICE) guidance sets out a diagnostic policy which is appropriate for the structure of health care in the UK in which patients present to a general practitioner (GP) who evaluates the symptoms and assesses whether investigation is appropriate (3) . Where there is a question of ovarian cancer, as when a woman presents with abdominal 'bloating', abdominal or pelvic pain, early satiety or urinary symptoms, the NICE guidelines require measurement of the serum CA125 with subsequent investigation by pelvic ultrasound when that value exceeds 35 u/ml, the established cut off value (4) . If findings support the diagnosis of ovarian cancer there should be urgent referral to a gynaecologist for further evaluation and treatment. Lower values carry information about residual ovarian tumour after first line treatment (5) and changes in the value below the cut off are important in screening (6) .
We have previously reported on the effect of the introduction of the NICE guidelines on the number of CA125 measurements at this hospital (7) . In the 6 months before the NICE guidance appeared, there were 486 measurements in the laboratory from nearby GPs which rose by 170% after publication. We now report a detailed analysis of CA125 tumour marker measurements from local primary care in 2014 and an analysis of all cases of ovarian cancer diagnosed between 2013 and 2015 with the aim of identifying the place of this test in cancer diagnosis and seeking to suggest ways in which the attainment of early diagnosis might be developed.
Methods
Data from the Laboratory Information Management system (Sunquest Fordman) of Airedale Hospital of CA125 measurements in females in primary care during 2014 were retrieved and from these we selected those originating from primary care practices whose patients are routinely referred to Airedale. This was to maximize the proportion of patients in whom it could be reliably assessed what further management had occurred.
The ICE system (Sunquest Information Systems) used at Airedale General Hospital stores laboratory reports derived from the Fordman system and radiology reports for all users of services provided by its managing Trust. The available electronic records were scrutinized for those values that were designated abnormal, defined as in the guideline (3) and by convention as 35 u/ml or above. In addition, note was taken of the number of measurements between 20 and 35 u/ml. The records of values over 35 u/ml were scrutinized and the number of patients ascertained. Where the initial elevated CA125 had been recognized before January 2014 the patient was excluded from further analysis; that is to say we studied incident new elevated CA125 values. We noted what laboratory and radiological investigations were carried out following the index CA125 measurement as recorded in the ICE database.
Using its database of patients assessed, we further studied all the patients recorded as being discussed by the local gynaecological multidisciplinary team and who had this disease diagnosed during 2013-2015, whether or not subsequent management was meant to be undertaken by them, and the CA125 values were noted.
Any ambiguities about patients' diagnoses were addressed by access to electronic records of the cancer services and those contained in the patient administration system.
Results
The hospital laboratory measured 4379 samples for CA125 which originated in primary care during 2014. Of these 341 had a value of 35 u/ml or above (7.8%). Samples originating from primary care practices whose patients are routinely referred to Airedale clinicians amounted to 2904 measurements of which 242 were ≥35 u/ ml (8.3%).
From these 242 results, it was established that 164 were from newly incident cases of elevated CA125 and 152 [92.7%; 95% confidence interval (CI): 88.7-96.7%] had evidence of some further assessment, either radiological tests or referral to a consultant, not necessarily a gynaecologist, in the records available at Airedale (Fig. 1) . Sixteen of the 152 (11%) had a diagnosis of ovarian carcinoma or primary peritoneal carcinoma (PPC), the diagnosis of which was the object of the investigations. A further 16 had other malignancies and only 50 patients (33%) had no abnormality to account for the elevated CA125 identified. A negative ultrasound in 23 of these was the conclusion of the investigative process. An equivocal ultrasound report in two further patients led to referral to a gynaecologist without any pathology being found. Only one patient was referred to a gynaecologist after a clear negative ultrasound report. Seventeen (11% of all patients) had persistent elevated CA125 over several measurements, designated chronic elevated CA125 ( Between 2013 and 2015, 65 patients (including the 16 with CA125 measured in primary care in 2014) had a diagnosis of carcinoma of the ovary or PPC discussed in the hospital's multidisciplinary meeting. The CA125 values of these patients were widely and evenly scattered. Five cases had values within the normal range of less than 35 u/mL [sensitivity of the test 92.3% (95% CI: 85.8-98.8)] and measurements ranged up to 6000 with one outlying value of 30 900. It was possible to look back over the hospital record of CA125 measurement for these individuals and identify that six patients had CA125 measurements several months before the diagnosis of ovarian cancer was made, 5 of these (8%, 95% CI: 1-14%) were in the normal range but greater than 20 u/ml. The inference that is suggested by this is that the patient consulted the GP about relevant symptoms during this period for this test to be done. Perhaps further investigation was dissuaded because of the 'normal' value. In 2014, the Airedale population generated 364 samples 8.3% of the total, in the range 20-34.9 u/ml.
Discussion

Main findings
This study has taken place in routine clinical practice as it impinges on one NHS general hospital. These results show that the primary care community that is served by the hospital laboratory and by its clinical services has taken on the concept of measuring CA125 in women whose symptoms suggest the possibility of ovarian cancer and has been remarkably consistent in this approach since the NICE guidelines were published. We also found that, in spite of the fact that in responding to a survey most GPs said they would refer a patient with elevated CA125 to a gynaecologist even if the associated ultrasound examination was normal (8) there was no evidence of this regularly occurring. Notwithstanding this, the 2016 Pathfinder survey of 1343 ovarian cancer patients showed that the proportion of women attaining a diagnosis over 3 months after first consulting a GP was 45% and unchanged over previous iterations which cover the period immediately before and after publication of the guidance (9) . Not all ovarian cancers are diagnosed via this route and even when CA125 is included in the GP's assessment before referral of the patient, the values can be very high and in excess of those seen in the screening context. This may be because patients are attending primary care late or, as is suggested by the proportion of patients who have a long pre-diagnostic period in primary care because the GP has a high threshold for requesting the test. For some patients, the GP may have been inappropriately reassured by a test that was below threshold when it was initially measured as was the case with six of the cases in this audit.
On the other hand, some measurements are generated with values between 20 and 35. About one in eight measurements from primary care come into this area and it is very possible that investigation of patients with such values will bring about early diagnoses of ovarian cancer. However, in this primary care population, comorbidity is a significant cause of elevated CA125 and is no doubt also associated with values in the 20s and so to investigate all such patients would create a significant burden on the National Health Service and a source of anxiety to the many women who do not have a serious condition. A screening population can expect it to have fewer patients with comorbidity. When the prior probability of a condition is low diagnostic efficiency in primary care can be achieved by allowing time to pass before repeating a test (10) . This is inappropriate when the patient is presenting with an alarm symptom and urgent referral is unequivocally required. Ovarian cancer at its early presentation does not have alarm symptoms so the approach of using an interval when investigating in primary care can delay diagnosis (11) . The use of the CA125 blood test with a cut off of 35 u/ml to select such patients for referral is the current workable compromise but it is not perfect.
Strengths and limitations
This is a real-world assessment of the use of CA125 within the NICE guidance. As such, it is a retrospective review of the workload. We cannot know if all measurements were in patients who had symptoms suggestive of ovarian disease. We do not know if the eight individuals whose elevated CA125 values were not pursued further in Airedale General Hospital were referred elsewhere for the definitive investigations nor if any of them had ovarian cancer.
Interpretation
Measuring CA125 has, in general, been embraced in primary care in assessing women who might have ovarian cancer. When it formed part of the process of diagnosis it seems that this was not always done early. To understand this further it will be necessary to explore what opportunities to undertake the test occurred in primary care for those ovarian cancer patients who did not have it done. There is also the issue of timing of re-tests in patients with values <35 u/ml. We know from the UK FOCS Study that in the context of screening frequent assessment of CA125 is necessary to gain the advantage of superior clinical outcome from early detection (12) and analysis of changes over time in the value below the threshold is effective in that context (6) , so the policy we would advocate where symptoms persist with a value of CA125 of >20 u/ ml the patient should have the value repeated in the interval. An example of a case where this would have facilitated timely diagnosis is reported by Dilley et al. (13) . Our observations suggest that a lead time of 4 months can be expected amongst these so that in 2 months a 40% increase might be identified. This strategy should be explored in further studies.
There is great scope for looking at other tests. For example human epididymis protein 4 measurements have value in discriminating between benign and malignant gynaecological lesions (14) . Measurement of HE4 alongside CA125 might enhance the specificity of CA125 measurement. This coupled with a lower threshold of CA125 for investigation could be a route to higher sensitivity.
Conclusion
CA125 measured in primary care is a test with high specificity for identifying ovarian and primary peritoneal cancer. It is not, in practice, used in all cases and a lower cut off value might increase sensitivity but would be much less specific.
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